التصلب المتعدد
آخر تحديث 17 مارس 2026
يتوافق مع الإرشادات التحريرية
- تنزيلتنزيل
- مشاركة
- Language
- نقاش
- نسخة صوتية
- أضف إلى المصادر المفضلة على جوجل
Multiple sclerosis is a condition characterised by areas of damage (lesions) on the brain and spinal cord. These lesions are associated with destruction of the covering that protects nerves and promotes the efficient transmission of nerve impulses (the myelin sheath) and damage to nerve cells. Multiple sclerosis is considered an autoimmune disorder; autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs, in this case tissues of the nervous system.
الوصف
Multiple sclerosis is a condition characterised by areas of damage (lesions) on the brain and spinal cord. These lesions are associated with destruction of the covering that protects nerves and promotes the efficient transmission of nerve impulses (the myelin sheath) and damage to nerve cells. Multiple sclerosis is considered an autoimmune disorder; autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs, in this case tissues of the nervous system.
Multiple sclerosis usually begins in early adulthood, between ages 20 and 40. The symptoms vary widely, and affected individuals can experience one or more effects of nervous system damage. Multiple sclerosis often causes sensory disturbances in the limbs, including a prickling or tingling sensation (paresthesia), numbness, pain, and itching. Some people experience Lhermitte sign, which is an electrical shock-like sensation that runs down the back and into the limbs. This sensation usually occurs when the head is bent forward. Problems with muscle control are common in people with multiple sclerosis. Affected individuals may have tremors, muscle stiffness (spasticity), exaggerated reflexes (hyperreflexia), weakness or partial paralysis of the muscles of the limbs, difficulty walking, or poor bladder control. Multiple sclerosis is also associated with vision problems, such as blurred or double vision or partial or complete vision loss. Infections that cause fever can make the symptoms worse.
There are several forms of multiple sclerosis: relapsing-remitting MS, secondary progressive MS, primary progressive MS, and progressive relapsing MS. The most common is the relapsing-remitting form, which affects approximately 80 percent of people with multiple sclerosis. Individuals with this form of the condition have periods during which they experience symptoms, called clinical attacks, followed by periods without any symptoms (remission). The triggers of clinical attacks and remissions are unknown. After about 10 years, relapsing-remitting MS usually develops into another form of the disorder called secondary progressive MS. In this form, there are no remissions, and symptoms of the condition continually worsen.
Primary progressive MS is the next most common form, affecting approximately 10 to 20 percent of people with multiple sclerosis. This form is characterised by constant symptoms that worsen over time, with no clinical attacks or remissions. Primary progressive MS typically begins later than the other forms, around age 40.
Progressive relapsing MS is a rare form of multiple sclerosis that initially appears like primary progressive MS, with constant symptoms. However, people with progressive relapsing MS also experience clinical attacks of more severe symptoms.
Inheritance patterns
The source lists the following possible inheritance patterns: Pattern unknown. More than one pattern can apply in different cases.
Related genes
Other names
Disseminated sclerosis
MS
Related patient information and medicines

Patient information leaflet
التصلب المتعدد
Multiple sclerosis is a disorder of the brain and spinal cord. It can cause various symptoms. What is multiple sclerosis. Multiple sclerosis (MS) is a disease where patches of inflammation occur in parts of your brain and/or spinal cord. This can cause damage to parts of your brain and lead to various symptoms (described below). How common is.

Patient information leaflet
الجهاز المناعي
This leaflet gives a brief overview of the immune system and how it works. In autoimmune diseases the body is unable to tell what is its own and what... Autoimmune diseases can attack any part of the body - eg, type 1 diabetes (pancreas), التصلب المتعدد (brain and nerves), systemic lupus erythematosus (skin and organs). These diseases are.

Patient information leaflet
الالتهاب الرئوي الشفطي
Aspiration pneumonia is a lower respiratory tract (chest) infection caused by bacteria which have leaked into the lungs from fluid from the stomach or mouth. Aspiratio... This liquid causes a bacterial infection in the lungs. It is most common in people who have a condition making swallowing difficult - typically the very elderly, the very young.

Patient information leaflet
مرخيات العضلات
Muscle relaxants are used to relieve muscle spasms which may result from some conditions which affect the nervous system, such as: Multiple sclerosis. التصلب المتعدد Muscle relaxants used in MS include baclofen, tizanidine, gabapentin, diazepam, clonazepam, and dantrolene. Cannabis extract (Sativex®) is always started by a consultant in a.

Patient information leaflet
ألم العصب الثلاثي التوائم
Trigeminal neuralgia is defined as nerve pain (neuralgia) involving one or more of the branches of the trigemi... Much more rarely, trigeminal neuralgia is a symptom of another condition, like a tumour, التصلب المتعدد (MS), or an abnormality of the base of the skull. Therefore, a typical person with trigeminal neuralgia is an older person, has.

Patient information leaflet
هل يمكنني تناول الريشي والفطر الأبيض معًا؟
If you are taking insulin or other diabetes medications, monitor your blood sugar closely as your dose may need adjustment to pre... Auto-immune conditions (e.g., التصلب المتعدد،, lupus, rheumatoid arthritis) These supplements can increase immune system activity, which may worsen the symptoms of autoimmune diseases. Avoid use if you have these.
قراءة إضافية ومراجع
- التصلب المتعدد; MedlinePlus, National Library of Medicine.
- Albelo-Martinez M, Rizvi S. Progressive multiple sclerosis: Evaluating current therapies and exploring future treatment strategies. Neurotherapeutics. 2025 Jul;22(4):e00601. doi: 10.1016/j.neurot.2025.e00601. Epub 2025 May 9.
- Alcina A, Abad-Grau Mdel M, Fedetz M, Izquierdo G, Lucas M, Fernandez O, Ndagire D, Catala-Rabasa A, Ruiz A, Gayan J, Delgado C, Arnal C, Matesanz F. Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations. PLoS One. 2012;7(1):e29819. doi: 10.1371/journal.pone.0029819. Epub 2012 Jan 13.
- Balcerac A, Louapre C. Genetics and familial distribution of multiple sclerosis: A review. Rev Neurol (Paris). 2022 Jun;178(6):512-520. doi: 10.1016/j.neurol.2021.11.009. Epub 2022 Feb 9.
- Barkhof F, Reich DS, Oh J, Rocca MA, Li DKB, Sati P, Azevedo CJ, Bagnato F, Calabresi PA, Ciccarelli O, Dwyer MG, DeLuca GC, De Stefano N, Enzinger C, Filippi M, Granziera C, Halper J, Henry RG, Gasperini C, Gauthier S, Kappos L, Laule C, Newsome SD, Montalban X, Morrow SA, Schoonheim MM, Sicotte N, Toosy A, Wilken J, Yousry T, Sastre-Garriga J, Traboulsee A, Ontaneda D, Rovira A; Magnetic Resonance Imaging Network in Multiple Sclerosis; Consortium of Multiple Sclerosis Centers; North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group. 2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis. Lancet Neurol. 2025 Oct;24(10):866-879. doi: 10.1016/S1474-4422(25)00304-7.
- Goris A, Vandebergh M, McCauley JL, Saarela J, Cotsapas C. Genetics of multiple sclerosis: lessons from polygenicity. Lancet Neurol. 2022 Sep;21(9):830-842. doi: 10.1016/S1474-4422(22)00255-1.
- International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019 Sep 27;365(6460):eaav7188. doi: 10.1126/science.aav7188.
- International Multiple Sclerosis Genetics Consortium; MultipleMS Consortium. Locus for severity implicates CNS resilience in progression of multiple sclerosis. Nature. 2023 Jul;619(7969):323-331. doi: 10.1038/s41586-023-06250-x. Epub 2023 Jun 28.
- Kiani RA, Wattoo FH, Khan MU, Munir M, Sattar S, Kazmi M, Jamila, Rehman R, Shan MA, Ali Q, Iqbal A, Ali D. Impact of the CYP27B1 p.R389H mutation on protein stability and function: implications for multiple sclerosis pathogenesis. Sci Rep. 2025 Sep 26;15(1):33047. doi: 10.1038/s41598-025-07199-9.
- Kuhlmann T, Moccia M, Coetzee T, Cohen JA, Correale J, Graves J, Marrie RA, Montalban X, Yong VW, Thompson AJ, Reich DS; International Advisory Committee on Clinical Trials in Multiple Sclerosis. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023 Jan;22(1):78-88. doi: 10.1016/S1474-4422(22)00289-7. Epub 2022 Nov 18.
- Patsopoulos NA. Genetics of Multiple Sclerosis: An Overview and New Directions. Cold Spring Harb Perspect Med. 2018 Jul 2;8(7):a028951. doi: 10.1101/cshperspect.a028951.
- Sahi N, Ciccarelli O, Houlden H, Chard DT. Unlocking Multiple Sclerosis Genetics: From Susceptibility to Severity. Neurology. 2025 Oct 21;105(8):e214141. doi: 10.1212/WNL.0000000000214141. Epub 2025 Sep 26.
- Sorosina M, Santoro S, Ferre L, Mascia E, Clarelli F, Giordano A, Cannizzaro M, Lucia M, Martinelli V, Filippi M, Esposito F. Risk HLA Variants Affect the T-Cell Repertoire in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023 Feb 15;10(3):e200093. doi: 10.1212/NXI.0000000000200093. Print 2023 May.
- Vitturi BK, Cellerino M, Boccia D, Leray E, Correale J, Dobson R, van der Mei I, Fujihara K, Inglese M. Childhood and Adolescent Environmental Risk Factors for Multiple Sclerosis: A Systematic Review With Meta-Analysis. Eur J Neurol. 2025 Nov;32(11):e70398. doi: 10.1111/ene.70398.
- Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, Wallin M, Helme A, Angood Napier C, Rijke N, Baneke P. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020 Dec;26(14):1816-1821. doi: 10.1177/1352458520970841. Epub 2020 Nov 11.
- Ward M, Goldman MD. Epidemiology and Pathophysiology of Multiple Sclerosis. Continuum (Minneap Minn). 2022 Aug 1;28(4):988-1005. doi: 10.1212/CON.0000000000001136.
تاريخ المقال
المقال متاح أيضًا باللغة الإنجليزية, الألمانية, إسبانية, الفرنسية, إيطالي, البرتغالية, الهندية, العبرية, العربية ,، و السويدية.
17 مارس 2026 | أحدث إصدار
1 Apr 2013 | نُشر في الأصل
انضم إلى المحادثة
شارك أفكارك أو تجاربك مع الآخرين في مجتمعات المرضى.

اسأل، شارك، تواصل.
تصفح المناقشات، اطرح الأسئلة، وشارك التجارب عبر مئات المواضيع الصحية.
اشترك في النشرة الإخبارية للمرضى
جرعتك الأسبوعية من النصائح الصحية الواضحة والموثوقة - مكتوبة لمساعدتك على الشعور بالاطلاع والثقة والتحكم.
من خلال الاشتراك، فإنك تقبل سياسة الخصوصية. يمكنك إلغاء الاشتراك في أي وقت. نحن لا نبيع بياناتك أبدًا.